SE9604296D0 - New pharmaceutical formulation of polypeptides - Google Patents
New pharmaceutical formulation of polypeptidesInfo
- Publication number
- SE9604296D0 SE9604296D0 SE9604296A SE9604296A SE9604296D0 SE 9604296 D0 SE9604296 D0 SE 9604296D0 SE 9604296 A SE9604296 A SE 9604296A SE 9604296 A SE9604296 A SE 9604296A SE 9604296 D0 SE9604296 D0 SE 9604296D0
- Authority
- SE
- Sweden
- Prior art keywords
- lipid
- pharmaceutical formulation
- new pharmaceutical
- polypeptides
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to a new pharmaceutical formulation comprising a lipid aggregate of a negatively charged lipid or lipid mixture and at least one antigenic, native or recombinant polypeptide which constitute a Helicobacter pylori antigen, and optionally a pharmaceutically acceptable carrier. More specifically the invention relates to a lipid aggregate comprising a surface-exposed antigen with an approximate molecular weight of 29 kDa. Furthermore the invention provides a formulation of a nucleic acid molecule coding for the said polypeptide. The new formulations, which are useful as vaccine formulations, elicit a protective immune response against H. pylori infections, and said vaccine formulations are suitable for both therapeutic and prophylatic use.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9604296A SE9604296D0 (en) | 1996-11-22 | 1996-11-22 | New pharmaceutical formulation of polypeptides |
PCT/SE1997/001927 WO1998022135A1 (en) | 1996-11-22 | 1997-11-18 | Pharmaceutical lipid aggregate with helicobacter pylori antigen and negatively charged lipid |
AU51418/98A AU5141898A (en) | 1996-11-22 | 1997-11-18 | Pharmaceutical lipid aggregate with helicobacter pylori antigen and negatively charged lipid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9604296A SE9604296D0 (en) | 1996-11-22 | 1996-11-22 | New pharmaceutical formulation of polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
SE9604296D0 true SE9604296D0 (en) | 1996-11-22 |
Family
ID=20404716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE9604296A SE9604296D0 (en) | 1996-11-22 | 1996-11-22 | New pharmaceutical formulation of polypeptides |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU5141898A (en) |
SE (1) | SE9604296D0 (en) |
WO (1) | WO1998022135A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
AU783344B2 (en) * | 1999-02-17 | 2005-10-20 | Csl Limited | Immunogenic complexes and methods relating thereto |
GB0008877D0 (en) * | 2000-04-12 | 2000-05-31 | Astrazeneca Ab | Polypeptide delivery system |
GB0008879D0 (en) * | 2000-04-12 | 2000-05-31 | Astrazeneca Ab | Polypeptide delivery system |
GB0010371D0 (en) * | 2000-04-29 | 2000-06-14 | Astrazeneca Ab | Helicobacter pylori antigens |
CN105816858A (en) | 2007-12-28 | 2016-08-03 | 巴克斯特国际公司 | Recombinant vwf formulations |
US11197916B2 (en) | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
WO2010041143A2 (en) * | 2008-10-08 | 2010-04-15 | Immune Solutions Limited | Oral vaccines for producing mucosal immunity |
CN102387784B (en) | 2008-10-21 | 2014-04-02 | 巴克斯特国际公司 | Lyophilized recombinant vwf formulations |
CA3007036A1 (en) | 2015-12-14 | 2017-06-22 | Technische Universitat Munchen | Helicobacter pylori vaccines |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5643574A (en) * | 1993-10-04 | 1997-07-01 | Albany Medical College | Protein- or peptide-cochleate vaccines and methods of immunizing using the same |
-
1996
- 1996-11-22 SE SE9604296A patent/SE9604296D0/en unknown
-
1997
- 1997-11-18 WO PCT/SE1997/001927 patent/WO1998022135A1/en active Application Filing
- 1997-11-18 AU AU51418/98A patent/AU5141898A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU5141898A (en) | 1998-06-10 |
WO1998022135A1 (en) | 1998-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY119003A (en) | Bacterial antigens and vaccine compositions | |
TR200100936T2 (en) | Therapeutic vaccination | |
IS4518A (en) | New vaccine formulation | |
AR006999A1 (en) | AN IMMUNOGENIC, THERAPEUTIC OR PROPHYLACTIC COMPOSITION, INCLUDING AN ISOLATED POLYPEPTIDE, AN ISOLATED ANTIBODY THAT IS LINKED TO SUCH A POLYPEPTIDE AND A VACCINE THAT UNDERSTANDS IT. | |
NZ503763A (en) | Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use | |
EP1398379A3 (en) | Compounds for immunotherapy and diagnosis of tuberculosis | |
KR890701758A (en) | Analogs of Bordetella exotoxin subunits derived from recombinant DNA and vaccines comprising the same | |
EP2172551A3 (en) | Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use | |
SE9604296D0 (en) | New pharmaceutical formulation of polypeptides | |
KR910018033A (en) | Actinobacillus pleuropneumoniae subunit vaccine | |
Rask et al. | Mucosal and systemic antibody responses after peroral or intranasal immunization: Effects of conjugation to enterotoxin B subunits and/or of co‐administration with free toxin as adjuvant | |
BR9810907A (en) | Monoclonal and polyclonal antibodies, peptide capable of generating an antibody, immunogenic agent, nucleotide sequence, pharmaceutical composition, use of at least one antibody, diagnostic kit, and process for preparing an immunogenic agent | |
CA2014033A1 (en) | Compositions and treatments for pneumonia in animals | |
BR9812240A (en) | Altered g protein or rsv polypeptide, use of it, nucleic acid molecule encoding an altered g protein or rsv polypeptide, nucleic acid construction, recombinant host cell, processes of producing an altered g protein or rsv polypeptide immunogenic composition , to induce an immune response in a vertebrate, to inhibit the induction of disease increase after vaccination and subsequent infection of a vertebrate with rsv and to immunize a vertebrate against rsv, vaccine composition, vaccine, and, composition immunogenic | |
FI955150A (en) | Immunogenic formulations of OspC antigen vaccines for the prevention and treatment of lymphatic disease and recombinant methods for the production of antigens | |
DE69836520D1 (en) | Clostridium perfringens vaccine | |
DE69415462D1 (en) | SYNTHETIC PEPTIDES AND VACCINE AGAINST PARVOVIRUS | |
US8647636B2 (en) | Low antigen-dose immunization utilizing overlapping peptides for maximizing T-helper cell 1 (Th1) immunity against a pathogen | |
WO1999051188A3 (en) | A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof | |
PE20010237A1 (en) | GENE DERIVED FROM LAWSONIA AND OmpH POLYPEPTIDES, PEPTIDES AND RELATED PROTEINS AND THEIR USES | |
ATE385809T1 (en) | SAPONIN COMPOSITIONS AND THEIR USE | |
WO2002051237A3 (en) | Helicobacter proteins, nucleic acids and uses thereof | |
DE69928947D1 (en) | MORAXELLA CATARRHALIS BASB034 POLYPEPTIDES AND USES THEREOF | |
BR0112141A (en) | Peptides, polypeptide, composition, use of a peptide or polypeptide, and, antibody | |
BR9712968A (en) | Genes encoding mycobacterial proteins associated with cell ligand and cell registration and use of these |